Contact
searchSearch
HMP Global
Interventional Echo Exam

NBE Announces Examination and Certification of Special Competence in Interventional Echocardiography

Stephen H. Little, MD
11/10/2026

© 2026 HMP Global. All Rights Reserved.

Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Cath Lab Digest or HMP Global, their employees, and affiliates. 

Stephen H. Little, MD, is System Director for Structural Heart and Medical Director of the Valve Clinic at Houston Methodist DeBakey Heart & Vascular Center in Houston, Texas.

Dr. Little describes plans by the National Board of Echocardiography (NBE) for the new Examination and Certification of Special Competence in Interventional Echocardiography (IEeXAM). Debuting in 2028, the IEeXAM is for physicians specializing in interventional echocardiography in structural heart disease. Learn more here.

Watch the Video with Dr. Stephen Little

Related Content

Colin M. Barker, MD
Mitral Valve Intervention
Transcatheter Mitral Valve Replacement (TMVR): Patient Selection, Anatomical Barriers, and Complications in the Era of Emerging Devices
11/09/2026
Colin M. Barker, MD, FACC, FSCAI
Colin M. Barker, MD, FACC, FSCAI, Director, Section of Interventional Cardiology, and Associate Professor of Medicine at Vanderbilt Health in Nashville, Tennessee, shared his experience with transcatheter mitral valve replacement at the TCT...
Colin M. Barker, MD, FACC, FSCAI, Director, Section of Interventional Cardiology, and Associate Professor of Medicine at Vanderbilt Health in Nashville, Tennessee, shared his experience with transcatheter mitral valve replacement at the TCT...
Colin M. Barker, MD, FACC,...
11/09/2026
Cath Lab Digest
TAVR
TAVR Use Increased Nearly Ninefold Among Patients Under 70 in Health System Analysis
11/04/2026
Annual TAVR procedures among patients younger than 70 rose from 15 in 2014 to 134 in 2024 within one health system, driven primarily by patients in their 60s, while surgery remained predominant.
Annual TAVR procedures among patients younger than 70 rose from 15 in 2014 to 134 in 2024 within one health system, driven primarily by patients in their 60s, while surgery remained predominant.
Annual TAVR procedures among...
11/04/2026
Cath Lab Digest
transcatheter heart valves
Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026
11/03/2026
Anteris Technologies Global Corp. announced 30-day clinical and hemodynamic outcomes for the Medium-size DurAVR® Transcatheter Heart Valve (THV) in twenty-two severe aortic stenosis patients with medium aortic annuli (aortic annulus area 492...
Anteris Technologies Global Corp. announced 30-day clinical and hemodynamic outcomes for the Medium-size DurAVR® Transcatheter Heart Valve (THV) in twenty-two severe aortic stenosis patients with medium aortic annuli (aortic annulus area 492...
Anteris Technologies Global...
11/03/2026
Cath Lab Digest
TAVR for Moderate AS
PROGRESS Trial: TAVR Improves Outcomes for Patients with Moderate Aortic Stenosis and At-Risk Features
11/02/2026
In a randomized trial of patients with moderate AS and at least one at-risk feature, those who underwent earlier TAVR had improved outcomes at two years than those managed with clinical surveillance.
In a randomized trial of patients with moderate AS and at least one at-risk feature, those who underwent earlier TAVR had improved outcomes at two years than those managed with clinical surveillance.
In a randomized trial of...
11/02/2026
Cath Lab Digest

Subscriber

Cath Lab Digest Newsletter

Clinical & Industry News

Device Development
Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST Heart Pump for Patients with Cardiogenic Shock
11/09/2026
Cambridge, MA – Blackstone Life Sciences (BXLS) announced a $455 million collaboration with Boston Scientific Corporation to co-fund the development of the VITALYST™ Temporary Percutaneous Transvalvular Circulatory Support System program. The...
Cambridge, MA – Blackstone Life Sciences (BXLS) announced a $455 million collaboration with Boston Scientific Corporation to co-fund the development of the VITALYST™ Temporary Percutaneous Transvalvular Circulatory Support System program. The...
Cambridge, MA – Blackstone Life...
11/09/2026
Cath Lab Digest
George Dangas, MD, PhD
Awards
George Dangas, MD, PhD, Receives the Most Coveted Award From the American Heart Association’s Council on Clinical Cardiology
11/09/2026
Laennec Master Clinician Award recognizes his lifetime achievements in cardiovascular patient care and cardiology education.
Laennec Master Clinician Award recognizes his lifetime achievements in cardiovascular patient care and cardiology education.
Laennec Master Clinician Award...
11/09/2026
Cath Lab Digest
Heart Failure
DETECT-HF Pivotal Study Validates Cordio Medical’s Smartphone-Based Voice Analysis for Remote Heart Failure Monitoring
11/09/2026
The 563-patient blinded study found that HearO predicted more than 70% of heart failure events at an average of 24.6 days before they occurred, with high patient compliance and no device-related adverse events.
The 563-patient blinded study found that HearO predicted more than 70% of heart failure events at an average of 24.6 days before they occurred, with high patient compliance and no device-related adverse events.
The 563-patient blinded study...
11/09/2026
Cath Lab Digest
Clinical Trials
Evolocumab Lowers Risk of Heart Attacks by 20% Compared With Ezetimibe in a Large Real-World Study
11/09/2026
Amgen announced results from a large real-world study showing that treatment with Repatha® (evolocumab) reduced the risk of fatal or nonfatal heart attacks by 20% compared with ezetimibe in people with atherosclerotic cardiovascular disease...
Amgen announced results from a large real-world study showing that treatment with Repatha® (evolocumab) reduced the risk of fatal or nonfatal heart attacks by 20% compared with ezetimibe in people with atherosclerotic cardiovascular disease...
Amgen announced results from a...
11/09/2026
Cath Lab Digest
Cardiogenic Shock
SCAI Updates Cardiogenic Shock Classification to Sharpen Recognition and Track Treatment Response
11/09/2026
2026 expert consensus reinforces assessment of perfusion and patient trajectory, with expanded guidance across shock populations and care settings.
2026 expert consensus reinforces assessment of perfusion and patient trajectory, with expanded guidance across shock populations and care settings.
2026 expert consensus reinforces...
11/09/2026
Cath Lab Digest
Clinical Trials
PARAMOUNT, the First Randomized Trial of AI-Enabled Plaque-Based Care, Meets Primary Endpoint in Late-Breaking Results at AHA 2026
11/09/2026
Compared with usual care based on stress testing, care guided by AI-based quantitative coronary CT analysis (AI-QCT) improved diagnostic certainty and led to more patients receiving lipid-lowering therapy.
Compared with usual care based on stress testing, care guided by AI-based quantitative coronary CT analysis (AI-QCT) improved diagnostic certainty and led to more patients receiving lipid-lowering therapy.
Compared with usual care based...
11/09/2026
Cath Lab Digest
Clinical Trials
DAPT-SHOCK-AMI: Cangrelor Associated With Greater Recovery of Heart Function in Cardiogenic Shock Imaging Substudy
11/09/2026
Patients with acute myocardial infarction complicated by cardiogenic shock who received intravenous cangrelor had less microvascular obstruction and greater recovery of left ventricular function than those receiving crushed oral ticagrelor,...
Patients with acute myocardial infarction complicated by cardiogenic shock who received intravenous cangrelor had less microvascular obstruction and greater recovery of left ventricular function than those receiving crushed oral ticagrelor,...
Patients with acute myocardial...
11/09/2026
Cath Lab Digest
FFR CT Analysis
CT-Guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients
11/04/2026
Late-Breaking P4 study shows CT guidance delivers matched one-year clinical outcomes with shorter procedures, demonstrating pre-procedural CCTA can guide key PCI planning decisions. NAVIGATE-PCI shows Heartflow PCI Navigator drove...
Late-Breaking P4 study shows CT guidance delivers matched one-year clinical outcomes with shorter procedures, demonstrating pre-procedural CCTA can guide key PCI planning decisions. NAVIGATE-PCI shows Heartflow PCI Navigator drove...
Late-Breaking P4 study shows CT...
11/04/2026
Cath Lab Digest
Women and PE
SYMPHONY-PE IDE: First-in-Field Analysis Provides Encouraging Safety Findings for Women with Pulmonary Embolism
11/04/2026
Sub-analysis presented at TCT 2026 shows substantial clot burden reduction and improved right-heart function with the Symphony Thrombectomy System despite greater baseline cardiac stress in women
Sub-analysis presented at TCT 2026 shows substantial clot burden reduction and improved right-heart function with the Symphony Thrombectomy System despite greater baseline cardiac stress in women
Sub-analysis presented at TCT...
11/04/2026
Cath Lab Digest
Renal Denervation
TCT26: Renal Denervation with Medtronic Symplicity Shows Significant Blood Pressure Drops in SPYRAL AFFIRM Real-World Study
11/04/2026
Nearly nine out of 10 patients experienced a clinical benefit at six months. Medtronic receives FDA approval for U.S. labeling update to Symplicity blood pressure procedure, expanding clinical evidence informing treatment options
Nearly nine out of 10 patients experienced a clinical benefit at six months. Medtronic receives FDA approval for U.S. labeling update to Symplicity blood pressure procedure, expanding clinical evidence informing treatment options
Nearly nine out of 10 patients...
11/04/2026
Cath Lab Digest

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use